莫沙必利治疗胃食管反流的临床观察  

Treatment of gastroesophageal reflux with mosapride

作　　者：赵庆波[1] 寸志林[1] 刘剑[1] 乔着意[1] 

机构地区：[1]解放军324医院急诊科,重庆400020

出　　处：《西南国防医药》2012年第5期508-511,共4页Medical Journal of National Defending Forces in Southwest China

摘　　要：目的比较分析枸橼酸莫沙必利与雷贝拉唑钠治疗胃食管反流的临床疗效。方法入选80例胃食管反流患者,随机分成2组,每组40例,其中对照组予以雷贝拉唑钠治疗,研究组采用枸橼酸莫沙必利治疗。连续治疗4 w后,比较分析两组患者相关临床资料。结果 (1)治疗前,两组间的反流评分、烧心评分、胸痛评分、吞咽不适评分及总症状评分均无统计学差异(P>0.05);治疗后,研究组的上述评分均较对照组均有明显改善(P<0.05)。(2)治疗前,两组的下食道括约肌压力(LESP)、近端最大收缩波幅、远端最大收缩波幅及体部蠕动波传导速度均无统计学差异(P>0.05);治疗后,研究组的上述指标均较对照组明显改善(P<0.05)。(3)通过症状改善评估方法,对照组的总有效率为60.47%,研究组的总有效率为95.35%,二者具有统计学差异(P<0.05)。研究组治疗后内镜下反流性食管炎分级情况较对照组明显改善(P<0.05)。(4)两组在不良反应发生率方面没有统计学差异(P>0.05)。结论枸橼酸莫沙必利可以很好地改善食管下括约肌功能和食管内酸反流,具有较好的安全性与有效性。Objective To make comparison of clinical curative effects between citrate mosapride and rabeprazole sodium on gastroesophageal reflux disease（GERD）.Methods Eighty patients with GERD were selected and randomly divided into two groups with 40 ones in each group.The control group received the treatment with rabeprazole sodium,and the research group received the treatment with citrate mosapride.After the continuous treatment for 4 w,clinical data of these patients were compared and analyzed.Results（1）Before the treatment,there was no significant difference in reflux score,heartburn score,chest pain score,dysphagia score and total symptom score between the two groups（P0.05）.After the treatment,these scores of the research group were all significantly improved compared with those of the control group（P0.05）.（2）Before the treatment,there was no significant difference in lower esophageal sphincter pressure（LESP）,proximal maximum contraction amplitude,distal maximum contraction amplitude and conduction velocity of caudomedial part peristaltic wave between the two groups（P0.05）.After the treatment,these indexes of the research group were significantly improved compared with those of the control group（P0.05）.（3）The symptom improvement assessment method showed the total effective rate of the control group was 60.47% and the research group was 95.35%.There were significant differences between the two groups（P0.05）.After the treatment,the classification of reflux esophagitis in the research group was improved significantly compared with that in the control group（P0.05）.（4）There was on significant difference in the incidence of adverse reaction between the two groups（P0.05）.Conclusion Citrate mosapride can greatly improve the lower esophageal sphincter function and acid reflux in esophagus,and has fine safety and efficacy.

关 键 词：胃食管反流 雷贝拉唑 枸橼酸莫沙必利 疗效 

分 类 号：R573[医药卫生—消化系统]